Charles River Laboratories International (CRL) Slides 2.7% on Lower Volume

Shares of Charles River Laboratories International have moved -2.7% today, and are now trading at a price of $203.79. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 282,942 compared to the stock's average volume of 520,222.

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. Based in Wilmington, United States the company has 20,000 full time employees and a market cap of $10,430,563,328.

The company is now trading -17.19% away from its average analyst target price of $246.08 per share. The 12 analysts following the stock have set target prices ranging from $205.0 to $280.0, and on average give Charles River Laboratories International a rating of buy.

The stock's 52 week high is $262.0 per share and its 52 week low is $181.22. Based on Charles River Laboratories International's average net margin growth of 6.2% over the last 4 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2022-12-31 3,976,060 486,226 12.23 10.78
2021-12-31 3,540,160 390,982 11.04 -11.4
2020-12-31 2,923,933 364,304 12.46 29.66
2019-12-31 2,621,226 252,019 9.61 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.